Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Extension Protocol for Patients With Chronic Myelogenous Leukemia, Malignant Melanoma or Renal Cell Carcinoma That Have Responded to Treatment With Pegylated-Interferon α-2a or Roferon-A® in Prior Clinical Studies

NCT02829775 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02829775
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02829775 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Extension Protocol for Patients With Chronic Myelogenous Leukemia, Malignant Melanoma or Renal Cell Carcinoma That Have Responded to Treatment With Pegylated-Interferon α-2a or Roferon-A® in Prior Clinical Studies
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2/3
Overall status
Completed
Start date
January 31, 2004
Completion date
January 31, 2008
Enrollment
9 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myelogenous leukemia, malignant melanoma, renal cell carcinoma